- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02882815
Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Occluder (PFO)
August 7, 2018 updated by: Lifetech Scientific (Shenzhen) Co., Ltd.
Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale)
The purpose of the study is to collect more data about performance and safety of the device called "IrisFITTM PFO occluder". This data will be used to help more patients who will accept treatment with this device in the future.
Patients will undergo routine examination, procedure and follow-up. Related data will be collected and kept in a way that patient info is well protected.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Post Market Clinical Follow-up study.
Informed consent will be obtained from the patient or from a legally authorized representative of the patient at screening.
The patients will be screened (pre-procedure) to determine eligibility for the study.
At screening, patients will be assessed for study eligibility by the inclusion/exclusion criteria through their medical history, demographics and transthoracic echocardiography (TTE).
Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.
The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE).
All periprocedural procedures will be performed according to site´s standard of care..
The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure.
Safety will also be assessed at 12 months by telephone visit.
Study Type
Interventional
Enrollment (Actual)
85
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who are according to current international or local guidelines (and future revisions) and per physician discretion scheduled for interventional treatment of PFO.
- Patients who are willing and capable of providing informed consent and participating in all testing/or follow procedure associated with this study.
- Patients who are eligible for treatment with IrisFIT PFO occluder device. (Per physician discretion and device IFU).
Exclusion Criteria:
- PFO tunnel length <1 mm
- Women of childbearing potential who are or plan to become pregnant during the time of the study (method of assessment upon physician's discretion)
- Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: IrisFIT PFO Occluder
Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE).
All periprocedural procedures will be performed according to site´s standard of care..
The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure.
Safety will also be assessed at 12 months by telephone visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse device effects during the procedure up to the point of implanting the study device in the PFO, and during completion of the procedure
Time Frame: during completion of the procedure
|
Adverse device effects during the procedure up to the point of implanting the study device in the PFO, and during completion of the procedure
|
during completion of the procedure
|
Device related adverse event up to 1 month follow-up
Time Frame: 1 month post procedure
|
Device related adverse event up to 1 month follow-up
|
1 month post procedure
|
Device related adverse event up to 12 month follow-up
Time Frame: 12 month post procedure
|
Device related adverse event up to 12 month follow-up
|
12 month post procedure
|
Rate of accurate device placement
Time Frame: 6 month post procedure
|
Rate of accurate device placement
|
6 month post procedure
|
Incidence of device migration/malfunction
Time Frame: 6 month post procedure
|
Incidence of device migration/malfunction
|
6 month post procedure
|
Successful closure/procedure rate: Proper position of the occluder by imaging, with trivial to small or without residual shunt, 6 month after procedure).
Time Frame: 6 month post procedure
|
Successful closure/procedure rate: Proper position of the occluder by imaging, with trivial to small or without residual shunt, 6 month after procedure).
|
6 month post procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: HORST SIEVERT, CARDIOVÄSCULARES CENTRUM FRANKFURT GERMANY
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2014
Primary Completion (ACTUAL)
November 1, 2015
Study Completion (ACTUAL)
January 1, 2017
Study Registration Dates
First Submitted
August 3, 2016
First Submitted That Met QC Criteria
August 24, 2016
First Posted (ESTIMATE)
August 30, 2016
Study Record Updates
Last Update Posted (ACTUAL)
August 9, 2018
Last Update Submitted That Met QC Criteria
August 7, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PFO-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patent Foramen Ovale
-
Abbott Medical DevicesActive, not recruitingPFO - Patent Foramen OvaleJapan
-
W.L.Gore & AssociatesRecruitingStroke | PFO - Patent Foramen OvaleUnited States
-
Carag AGCompleted
-
Chinese Academy of Medical Sciences, Fuwai HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruitingMigraine | PFO - Patent Foramen OvaleChina
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
University of OregonEnrolling by invitationPatent Foramen OvaleUnited States
-
Wolfson Medical CenterUnknownClosure of the Foramen Ovale and Ductus ArteriosusIsrael
-
Lifetech Scientific (Shenzhen) Co., Ltd.Recruiting
-
University of OregonRecruiting
Clinical Trials on IrisFIT PFO Occluder
-
Abbott Medical DevicesActive, not recruitingPFO - Patent Foramen OvaleJapan
-
Occlutech International ABActive, not recruitingStroke | PFO - Patent Foramen OvaleFrance, Germany, Italy, Canada
-
Abbott Medical DevicesCompleted
-
Abbott Medical DevicesTerminatedMigraine | Patent Foramen Ovale | Migraine With Aura | PFOUnited Kingdom, Germany, Canada, Switzerland
-
SeptRx, Inc.UnknownHeart Septal Defects | Heart Defects, Congenital | Foramen Ovale, PatentGermany, France
-
Hangzhou Dinova EP Technology Co., LtdNot yet recruiting
-
Abbott Medical DevicesRecruitingStroke | Patent Foramen OvaleUnited States, Germany, Canada, Switzerland, Italy, Portugal, United Kingdom
-
Lifetech Scientific (Shenzhen) Co., Ltd.Recruiting
-
W.L.Gore & AssociatesRecruitingStroke | PFO - Patent Foramen OvaleUnited States
-
Abbott Medical DevicesApproved for marketingPatent Foramen Ovale | PFO